SCHEMBL740459

SCHEMBL740459

CCOC(=O)n1nc(NC(=O)c2ccc(OC3CCN(C)CC3)cc2)c2cc(C(=O)OC(C)(C)C)sc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 4/20 0.42
KIT P10721 2/20 0.42
GSK3B P49841 6/20 0.39
DYRK1A Q13627 6/20 0.39
WNT1 P04628 3/20 0.39
CLK2 P49760 2/20 0.39
CLK3 P49761 2/20 0.39
KDM4E B2RXH2 4/20 0.38
HSD17B10 Q99714 4/20 0.38
HPGD P15428 3/20 0.38
PDE7A Q13946 1/20 0.38
ALDH1A1 P00352 3/20 0.37
MAPK1 P28482 2/20 0.37
USP2 O75604 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
CHEK2 O96017 2/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL740430 0.90 FLT3 (0.45) FLT3KITGSK3BDYRK1AWNT1
SCHEMBL742948 0.87 AURKA (0.47) FLT3KITGSK3BDYRK1AWNT1
SCHEMBL741671 0.86 AURKA (0.46) FLT3KITHSD17B10HPGDPDE7A
SCHEMBL740739 0.84 IKBKE (0.42) FLT3KITMAPK1SMN1; SMN2LMNA
SCHEMBL740373 0.83 FLT3 (0.43) FLT3KITGSK3BDYRK1AWNT1
SCHEMBL742441 0.83 ADORA2A (0.46) KDM4EHPGDPDE7AALDH1A1LMNA
SCHEMBL741049 0.81 PDE7A (0.37) KDM4EHSD17B10HPGDPDE7AALDH1A1
SCHEMBL739309 0.81 CSNK1D (0.45) KDM4EHPGDPDE7AALDH1A1MAPK1
SCHEMBL5980858 0.79 PDE7A (0.35) KDM4EHSD17B10HPGDPDE7AALDH1A1
Hydrochloric Acid SCHEMBL5981340 0.78 CSNK1D (0.42) KDM4EHPGDPDE7AALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481584-B2 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-07-09 US disclosed
US-20120165311-A1 1H-THIENO[2,3-C]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-06-28 US disclosed
US-8138217-B2 Aurora kinase inhibitors; proliferative disorders; anticancer agents; antitumor agents; N-(1-methyl-1-phenylethyl)-3-((4-morpholin-4-ylbenzoyl)amino)-1H-thieno(2,3-c)pyrazole-5-carboxamide NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-03-20 US disclosed
EP-1711177-B1 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS PFIZER ITALIA SRL (IT) 2008-05-28 EP disclosed
EP-1711177-A1 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS Pfizer Italia S.r.l. (IT) 2006-10-18 EP disclosed
US-20050187209-A1 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors PHARMACIA ITALIA S.P.A. (IT) 2005-08-25 US disclosed
WO-2005074922-A1 1H-THIENO[2,3-c]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS PFIZER ITALIA S.R.L. (IT) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165311-A1 1H-THIENO[2,3-C]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS MAP3K19, MAP3K1, MAP3K3 FLT3 327/4885KIT 795/4885GSK3B 429/4885
US-20050187209-A1 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors MAP3K19, MAP3K1, MAP3K3 FLT3 329/4885KIT 795/4885GSK3B 427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.